818.93
price down icon1.30%   -10.81
 
loading
Schlusskurs vom Vortag:
$829.74
Offen:
$828
24-Stunden-Volumen:
4.65M
Relative Volume:
1.53
Marktkapitalisierung:
$782.99B
Einnahmen:
$40.86B
Nettoeinkommen (Verlust:
$8.37B
KGV:
151.11
EPS:
5.4193
Netto-Cashflow:
$-2.28B
1W Leistung:
-8.26%
1M Leistung:
-7.41%
6M Leistung:
+5.43%
1J Leistung:
+47.70%
1-Tages-Spanne:
Value
$816.73
$833.00
1-Wochen-Bereich:
Value
$769.00
$907.98
52-Wochen-Spanne:
Value
$561.65
$972.53

Lilly Eli Co Stock (LLY) Company Profile

Name
Firmenname
Lilly Eli Co
Name
Telefon
(317) 276-2000
Name
Adresse
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Name
Mitarbeiter
43,000
Name
Twitter
@LillyPad
Name
Nächster Verdiensttermin
2024-10-30
Name
Neueste SEC-Einreichungen
Name
LLY's Discussions on Twitter

Lilly Eli Co Stock (LLY) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-10-17 Eingeleitet Bernstein Outperform
2024-09-13 Fortgesetzt Citigroup Buy
2024-08-12 Hochstufung Deutsche Bank Hold → Buy
2024-02-21 Herabstufung DZ Bank Buy → Hold
2024-02-16 Bestätigt Morgan Stanley Overweight
2023-12-21 Herabstufung Daiwa Securities Buy → Outperform
2023-11-09 Eingeleitet Deutsche Bank Hold
2023-10-20 Fortgesetzt UBS Buy
2023-08-09 Hochstufung Jefferies Hold → Buy
2023-07-26 Bestätigt Citigroup Buy
2023-07-14 Eingeleitet HSBC Securities Buy
2023-05-24 Bestätigt BofA Securities Buy
2023-05-24 Bestätigt UBS Buy
2023-03-13 Hochstufung Wells Fargo Equal Weight → Overweight
2023-03-06 Eingeleitet Jefferies Hold
2023-02-15 Herabstufung Societe Generale Hold → Sell
2022-11-18 Eingeleitet Credit Suisse Outperform
2022-09-22 Hochstufung UBS Neutral → Buy
2022-05-23 Eingeleitet SVB Leerink Outperform
2022-04-06 Fortgesetzt Morgan Stanley Overweight
2022-03-10 Eingeleitet Daiwa Securities Outperform
2022-01-21 Hochstufung DZ Bank Hold → Buy
2022-01-03 Bestätigt Bernstein Mkt Perform
2021-12-17 Eingeleitet Goldman Neutral
2021-12-16 Bestätigt BMO Capital Markets Outperform
2021-12-16 Bestätigt BofA Securities Buy
2021-12-09 Fortgesetzt Wells Fargo Equal Weight
2021-11-19 Eingeleitet BMO Capital Markets Outperform
2021-10-11 Hochstufung Berenberg Hold → Buy
2021-09-29 Hochstufung Citigroup Neutral → Buy
2021-08-05 Hochstufung DZ Bank Hold → Buy
2021-07-27 Fortgesetzt Truist Buy
2021-06-24 Bestätigt Cantor Fitzgerald Overweight
2021-01-19 Hochstufung Mizuho Neutral → Buy
2020-12-10 Hochstufung Wolfe Research Peer Perform → Outperform
2020-11-10 Fortgesetzt Bernstein Mkt Perform
2020-09-29 Eingeleitet Berenberg Hold
2020-09-03 Hochstufung Morgan Stanley Equal-Weight → Overweight
2020-06-16 Hochstufung Guggenheim Neutral → Buy
2020-04-21 Herabstufung UBS Buy → Neutral
2020-04-09 Herabstufung Morgan Stanley Overweight → Equal-Weight
2020-02-06 Eingeleitet Mizuho Neutral
2019-12-18 Hochstufung Morgan Stanley Equal-Weight → Overweight
2019-10-17 Fortgesetzt BofA/Merrill Buy
2019-05-28 Eingeleitet Goldman Buy
2019-04-24 Hochstufung Edward Jones Hold → Buy
2019-04-11 Herabstufung Guggenheim Buy → Neutral
2019-03-12 Eingeleitet JP Morgan Overweight
2019-01-23 Eingeleitet UBS Buy
2018-11-26 Herabstufung Citigroup Buy → Neutral
2018-10-31 Hochstufung Credit Suisse Underperform → Neutral
2018-10-09 Eingeleitet Guggenheim Buy
2018-10-01 Bestätigt SunTrust Buy
2018-09-26 Fortgesetzt JP Morgan Overweight
Alle ansehen

Lilly Eli Co Aktie (LLY) Neueste Nachrichten

pulisher
06:18 AM

Merus annonce ses résultats financiers pour le troisième trimestre 2024 et fait le point sur ses activités - GlobeNewswire Inc.

06:18 AM
pulisher
Nov 01, 2024

Eli Lilly grows Milwaukee-area footprint with $40.8M warehouse acquisition — and more - The Business Journals

Nov 01, 2024
pulisher
Nov 01, 2024

Hims & Hers Health Faces Pressure Ahead of Earnings Amid Eli Lilly's GLP-1 News - Yahoo Finance UK

Nov 01, 2024
pulisher
Nov 01, 2024

Eli Lilly’s Q3 Miss for Mounjaro, Zepbound Highlights Dependency on Wholesalers - BioSpace

Nov 01, 2024
pulisher
Nov 01, 2024

Eli Lilly Stock: Is LLY Stock A Sell After Its Disastrous Third-Quarter Report? - Investor's Business Daily

Nov 01, 2024
pulisher
Nov 01, 2024

Why Eli Lilly Is a No-Brainer Stock to Buy on the Dip - MSN

Nov 01, 2024
pulisher
Nov 01, 2024

ViaNautis signs multi-year collaboration with Eli Lilly and Company - Business Weekly

Nov 01, 2024
pulisher
Oct 31, 2024

Friday Five – Humira humbled, Lilly investors get trick instead of treat, Pfizer seeks to show up Starboard… and more - FirstWord Pharma

Oct 31, 2024
pulisher
Oct 31, 2024

Eli Lilly and the British government partner to provide GLP-1 weight loss medication to people who have obesity - HR Brew

Oct 31, 2024
pulisher
Oct 31, 2024

Lilly’s earnings surprise, investors mull the election, & a spooky ghost story - STAT

Oct 31, 2024
pulisher
Oct 31, 2024

Eli Lilly viewed positively despite Mounjaro, Zepbound disappointmentBoA - Proactive Investors USA

Oct 31, 2024
pulisher
Oct 31, 2024

Eli Lilly Shares Hit Yearly Low After Disappointing Q3 Earnings - Yahoo Finance

Oct 31, 2024
pulisher
Oct 31, 2024

Eli Lilly and Company (NYSE:LLY): Among The 10 Best S&P 500 Stocks to Buy According to Hedge Funds - Insider Monkey

Oct 31, 2024
pulisher
Oct 31, 2024

ELI LILLY AND COMPANY : Jefferies remains its Buy rating - Marketscreener.com

Oct 31, 2024
pulisher
Oct 31, 2024

Eli Lilly core thesis ‘remains intact’ despite Q3 miss, says JPMorgan - Yahoo Finance

Oct 31, 2024
pulisher
Oct 31, 2024

Are Eli Lilly's Lowered Expectations a Reason to Sell? - The Motley Fool

Oct 31, 2024
pulisher
Oct 31, 2024

Eli Lilly and Co (LLY) Q3 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic ... - Yahoo Finance

Oct 31, 2024
pulisher
Oct 31, 2024

Eli Lilly and Co (LLY): A Strategic SWOT Insight into Pharma's Future - Yahoo Finance UK

Oct 31, 2024
pulisher
Oct 31, 2024

Nasdaq edges back from its record as chip companies and Eli Lilly slump - The Decatur Daily

Oct 31, 2024
pulisher
Oct 30, 2024

Stocks hit pause after Nasdaq milestone; Eli Lilly earnings underwhelm Wall St. - The Post and Courier

Oct 30, 2024
pulisher
Oct 30, 2024

Health Care Down as Eli Lilly Slides -- Health Care Roundup - MarketWatch

Oct 30, 2024
pulisher
Oct 30, 2024

Eli Lilly & Co. stock underperforms Wednesday when compared to competitors - MarketWatch

Oct 30, 2024
pulisher
Oct 30, 2024

Stock market today: Nasdaq edges back from its record as chip companies and Eli Lilly slump - Oneonta Daily Star

Oct 30, 2024
pulisher
Oct 30, 2024

Wall Street indexes edge lower Wednesday as Alphabet jumps and Eli Lilly slumps - Greater Milwaukee Today | GMToday.com

Oct 30, 2024
pulisher
Oct 30, 2024

AMD, Eli Lilly slide; Google, Visa rise among Wednesday's afternoon market cap stock movers - Investing.com

Oct 30, 2024
pulisher
Oct 30, 2024

Crude Oil Gains Over 2%; Eli Lilly Cuts 2024 Forecast - Benzinga

Oct 30, 2024
pulisher
Oct 30, 2024

Lilly’s Mounjaro, Zepbound drugs see strong demand. So why did sales disappoint? - MarketWatch

Oct 30, 2024
pulisher
Oct 30, 2024

Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed - CNBC

Oct 30, 2024
pulisher
Oct 30, 2024

Eli Lilly’s third quarter earnings miss and forecast cut lead to sharp stock drop - LPHeraldDispatch.com

Oct 30, 2024
pulisher
Oct 30, 2024

Knockoff weight loss drugs are having a moment. Eli Lilly isn't worried - Yahoo! Voices

Oct 30, 2024
pulisher
Oct 30, 2024

Eli Lilly (LLY) Q3 2024 Earnings Call Transcript - The Motley Fool

Oct 30, 2024
pulisher
Oct 30, 2024

Eli Lilly plans to begin advertising weight-loss drug Zepbound - Yahoo Finance

Oct 30, 2024
pulisher
Oct 30, 2024

Eli Lilly’s slip does not mean the weight loss drug craze is over - Financial Times

Oct 30, 2024
pulisher
Oct 30, 2024

Stock movers: Alphabet, Super Micro, Eli Lilly and more - TheStreet

Oct 30, 2024
pulisher
Oct 30, 2024

Stock market today: Wall Street wavers as Alphabet jumps on Google profits and Eli Lilly slumps - Ottumwacourier

Oct 30, 2024
pulisher
Oct 30, 2024

Eli Lilly had a strong Q3, so why is its stock falling? - Seeking Alpha

Oct 30, 2024
pulisher
Oct 30, 2024

Eli Lilly Earnings: Maintaining Our Fair Value and Long-Term GLP-1 Forecast Despite Weaker Q3 - Morningstar

Oct 30, 2024
pulisher
Oct 30, 2024

Lilly Cuts Outlook After Obesity Drug Sales Post First Miss - Bloomberg

Oct 30, 2024
pulisher
Oct 30, 2024

Eli Lilly's rare sales miss for weight-loss drug sends shares tumbling - Reuters

Oct 30, 2024
pulisher
Oct 30, 2024

Eli Lilly: The Stock Might Have Peaked (NYSE:LLY) - Seeking Alpha

Oct 30, 2024
pulisher
Oct 30, 2024

Lilly's Q3 Earnings Miss, Mounjaro, Zepbound Disappoint, Stock Tanks - Yahoo Finance

Oct 30, 2024
pulisher
Oct 30, 2024

Lilly cuts outlook on surprising weight-loss drug disappointment - Detroit News

Oct 30, 2024
pulisher
Oct 30, 2024

Why Eli Lilly Stock Is Sinking Today - The Motley Fool

Oct 30, 2024
pulisher
Oct 30, 2024

Lilly shares tumble on earnings report that falls short of Wall Street expectations - Inside INdiana Business

Oct 30, 2024
pulisher
Oct 30, 2024

Stock market today: Wall Street churns near records as Alphabet jumps and Eli Lilly slumps - News-Press Now

Oct 30, 2024
pulisher
Oct 30, 2024

Eli Lilly shares tumble as company’s weight-loss drug misses Wall Street sales expectations - The Globe and Mail

Oct 30, 2024
pulisher
Oct 30, 2024

Have Eli Lilly's weight-loss drug gains hit a plateau? - Sherwood News

Oct 30, 2024
pulisher
Oct 30, 2024

Stock market today: Wall Street churns as Alphabet jumps, Eli Lilly tumbles - Ottumwacourier

Oct 30, 2024
pulisher
Oct 30, 2024

Drugmaker Eli Lilly dials back 2024 forecast after 3Q earnings miss - WTHR

Oct 30, 2024
pulisher
Oct 30, 2024

Drugmaker Eli Lilly walks back 2024 forecast after 3Q earnings miss - Bozeman Daily Chronicle

Oct 30, 2024
pulisher
Oct 30, 2024

Eli Lilly stock sinks after Q3 earnings miss Wall Street expectations - Yahoo Finance

Oct 30, 2024

Finanzdaten der Lilly Eli Co-Aktie (LLY)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
drug_manufacturers_general NVO
$111.94
price down icon 0.01%
$203.55
price down icon 0.16%
drug_manufacturers_general JNJ
$160.13
price up icon 0.17%
drug_manufacturers_general MRK
$101.88
price down icon 0.43%
drug_manufacturers_general NVS
$109.35
price up icon 0.88%
Kapitalisierung:     |  Volumen (24h):